NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/05/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,881.27 mln
Float7.81 mln
Earnings Date05/20/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
0.44
Highly suspicious
1-Year Forecast
300
Transformational upside
Relative Strength
99
/ 100
Top performer
Debt / Equity
13.39
Extremely leveraged
ROE
-205
Deeply negative
Business Description
Founded in 2024 and headquartered in La Jolla, California, Inhibrx Biosciences is an early-stage company focused on creating new medicines for patients facing serious and life-threatening diseases. The company is advancing two key treatments through clinical trials: one targeting a rare form of bone cancer that cannot be surgically removed, and another aimed at several types of advanced solid tumors including lung cancer, melanoma, and kidney cancer. Both treatments are designed using specialized biological approaches intended to more precisely engage the body's own systems to fight disease.
